Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer

Launched by HUNAN PROVINCE TUMOR HOSPITAL · Mar 16, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a combination treatment of IBI-322 and Lenvatinib for patients with extensive stage small cell lung cancer (SCLC) who did not respond well to their first treatment with PD-(L)1 inhibitors. The goal is to see how effective this new treatment is and to identify specific biological markers that might explain how it works. This is a Phase 2 trial, which means it’s looking at how well the treatment works in a larger group of people after it has shown promise in earlier studies.

To be eligible for the trial, participants must be between 18 and 75 years old, have a confirmed diagnosis of extensive stage SCLC, and have experienced progression of their cancer after using PD-(L)1 inhibitors. They should also have measurable cancer lesions that can be assessed through imaging tests. If you join the study, you can expect regular medical check-ups and monitoring throughout the treatment. It’s important to note that the trial is currently recruiting participants, and anyone interested in joining should discuss it with their healthcare provider for more information.

Gender

ALL

Eligibility criteria

• * Eligible subjects selected for this study must meet all of the following criteria:
• • 1. Sign written informed consent before implementing any trial-related procedures;
• • 2. Age ≥18 years old and ≤75 years old;
• • 3. No limit on the gender;
• • 4. Patients with extensive stage SCLC diagnosed by pathology (as staged by the American Veterans Lung Cancer Association (VALG)), who do not have an imaging response during first-line treatment with PD-(L)1 inhibitors, or who progress after imaging reactions on first-line therapy (the most recent regimen prior to enrollment must contain PD-(L)1 inhibitors);
• • 5. According to the Response Evaluation Criteria for Solid Tumors (RECIST V1.1), there must be at least one lesion that can be measured by imaging. Lesions located within the radiation field of previous radiation therapy can be considered as measurable lesions if progress is confirmed;
• • 6. ECOG score 0-1 points;
• • 7. Expected survival time\> 3 months;
• 8. Sufficient organ function, subjects need to meet the following laboratory indicators:
• • <!-- -->
• • 1. The absolute value of neutrophils (ANC) ≥1.5x109/L when no granulocyte colony-stimulating factor is used in the past 14 days;
• • 2. In the case of no blood transfusion in the past 14 days, platelets ≥100×109/L;
• • 3. In the past 14 days without blood transfusion or erythropoietin, hemoglobin\>9g/dL;
• • 4. Total bilirubin≤1.5×upper limit of normal (ULN);
• • 5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) within ≤2.5×ULN (subjects with liver metastases are allowed to have ALT or AST ≤5×ULN);
• • 6. Serum creatinine ≤1.5×ULN and creatinine clearance rate (calculated by Cockcroft-Gault formula) ≥50ml/min;
• • 7. Good coagulation function, defined as International Normalized Ratio (INR) or Prothrombin Time (PT) ≤ 1.5 times ULN;
• • 8. Normal thyroid function is defined as thyroid-stimulating hormone (TSH) within the normal range. If the baseline TSH is out of the normal range, subjects whose total T3 (or FT3) and FT4 are within the normal range can also be included in the group;
• • 9. Myocardial enzyme spectrum is within the normal range (for example, simple laboratory abnormalities that are judged by the investigator to be of no clinical significance are also allowed to be included in the group).
• Exclusion Criteria:
• • Patients with contraindication of chemotherapy Pregnant or breast feeding women